A Phase I, Multiple Ascending Dose Study of BMS-663513, an Agonistic Anti-CD137 Monoclonal Antibody, Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
To assess the safety and tolerability of multiple ascending doses of BMS-663513 when given in combination with paclitaxel and carboplatin to subjects with advanced malignancies
throughout the study
Yes
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
United States: Food and Drug Administration
CA186-004
NCT00351325
September 2007
March 2009
Name | Location |
---|---|
University of Washington | Seattle, Washington 98195 |
University of Virginia | Charlottesville, Virginia 22908 |
University of Pennsylvania Medical Center | Philadelphia, Pennsylvania 19104 |
Magee-Womens Hospital of UPMC | Pittsburgh, Pennsylvania 15213 |